Health Insurance (Indium-labelled Octreotide Study) Determination 2010

Overview

The Health Insurance (Indium-labelled Octreotide Study) Determination 2010, enacted by the Australian Parliament, is a legislative instrument aimed at integrating the Indium-labelled Octreotide Study service into the existing Medicare framework. This determination was introduced to address the need for the service to be managed consistently with other nuclear medicine services, following its evaluation by the Medical Services Advisory Committee in 1999. The primary objective of this determination is to remove the necessity for separate monitoring and evaluation of the service's volume and cost, allowing it to be overseen like other Medicare-eligible nuclear medicine services from 1 July 2010. The enactment of this determination by the Minister for Health and Ageing under the Health Insurance Act 1973 ensures that the service is now listed in the diagnostic imaging services table, thus streamlining its administration and funding within the Medicare system.

Scope and Application

The Health Insurance (Indium-labelled Octreotide Study) Determination 2010 applies to the Indium-labelled Octreotide Study, a diagnostic imaging service used to determine gastro-entero-pancreatic endocrine tumours. This Determination operates under the Health Insurance Act 1973, which governs the administration and funding of medical services in Australia. The Act applies to all persons and entities involved in the provision of health services, including healthcare providers, patients, and health insurers. The Determination itself, being a legislative instrument, has a national reach across the Commonwealth of Australia. The Determination revokes the previous Health Insurance (Indium-labelled Octreotide Study) Determination HS/09/2006, made under subsection 3C(1) of the Act, to streamline the arrangements for the funding of the specified diagnostic service. This change comes into effect from 1 July 2010, aligning the service with other Medicare eligible nuclear medicine services, as it is no longer necessary to monitor and evaluate the volume of the service and its cost to the Medicare outlays. The Determination does not explicitly state any exclusions or exemptions, and the addition of the service to the diagnostic imaging services table ensures consistent management with other similar services.

Key Provisions

The Health Insurance (Indium-labelled Octreotide Study) Determination 2010 (sections 1-3) specifies the name of the determination, its commencement date, and the revocation of a previous determination. Specifically, Section 1 names the determination as the Health Insurance (Indium-labelled Octreotide Study) Determination 2010, while Section 2 indicates that the determination commences on 1 July 2010. Section 3 revokes the Health Insurance (Indium-labelled Octreotide Study) Determination HS/09/2006, making the 2010 determination the current instrument governing the service. Under this determination, the primary obligation is the addition of the Indium-labelled Octreotide Study service to the diagnostic imaging services table in the Health Insurance (Diagnostic Imaging Services Table) Regulations. This addition is effective from 1 July 2010, ensuring that the service is managed like all other Medicare-eligible nuclear medicine services. The determination also facilitates the removal of the need to monitor and evaluate the volume of the service and its cost to Medicare outlays, as the service is now included in the table. The determination imposes a requirement on relevant parties, including healthcare providers and Medicare, to adhere to the updated arrangements for the funding and indexing of the Indium-labelled Octreotide Study service. This includes ensuring that the service is billed and reimbursed according to the fees specified in the Health Insurance (Diagnostic Imaging Services Table) Regulations, which are indexed in line with other nuclear medicine items. There are no specific offences, penalties, or civil/criminal consequences outlined in the determination itself. However, any breaches of the Health Insurance Act 1973 or related regulations, including improper billing or misuse of the service, could result in civil or criminal penalties under the general provisions of the Act. Such penalties may include fines, imprisonment, or both, depending on the nature and severity of the breach. The maximum penalties for offences under the Act are detailed in the relevant sections of the Act and could vary based on the specific circumstances of the case.